Westborough, MA, United States of America

Zhendong Zhu

This inventor holds 20 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: Celgene Car LLC, Celgene Avilomics Research, Inc., Sanofi. Active years: 2015-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhendong Zhu. Retrieved from https://idiyas.com/inventor/zhendong-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 7)

% Patents Active = 85.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 7.8

ph-index = 8

Forward Citations = 138(Granted Patents)

Company Filing History:

Celgene Avilomics Research, Inc.

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

Areas of Expertise:

Ligand-Directed Modification

MK2 Inhibitors

Heteroaryl Compounds

Protein Kinase Conjugates

Pyrido[2,3-d]Pyrimidines

ERK Inhibitors

Covalent Modification

Chemical Compounds

Pharmaceutical Uses

Biological Activity

Inhibitor Development

Targeted Therapy

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542492 - Ligand-directed covalent modification of protein (2023-01-03),

2. 11098061 - MK2 inhibitors and uses thereof (2021-08-24),

3. 10774052 - Heteroaryl compounds and uses thereof (2020-09-15),

4. 10662195 - Protein kinase conjugates and inhibitors (2020-05-26),

5. 10618902 - Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases (2020-04-14),

6. 10189794 - Heteroaryl compounds and uses thereof (2019-01-29),

7. 10138256 - MK2 inhibitors and uses thereof (2018-11-27),

8. 10065966 - Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases (2018-09-04),

9. 9980964 - ERK inhibitors and uses thereof (2018-05-29),

10. 9796700 - ERK inhibitors and uses thereof (2017-10-24),

11. 9695132 - Heteroaryl compounds and uses thereof (2017-07-04),

12. 9663524 - Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors (2017-05-30),

13. 9561228 - ERK inhibitors and uses thereof (2017-02-07),

14. 9556426 - Protein kinase conjugates and inhibitors (2017-01-31),

15. 9549927 - Heteroaryl compounds and uses thereof (2017-01-24),

Title: The Innovative Journey of Zhendong Zhu: A Leader in Protein Modification Patents

Introduction: Zhendong Zhu, a prolific inventor based in Westborough, MA, has made significant contributions to the field of biochemistry and pharmacology with his impressive portfolio of 20 patents. His work primarily focuses on enzyme inhibitors and innovative methods for protein modification, paving the way for advancements in therapeutic formulations.

Latest Patents: Among his latest inventions, Zhendong Zhu has developed two noteworthy patents. The first, titled "Ligand-directed covalent modification of protein," pertains to enzyme inhibitors. This invention encompasses methods for designing ligand-directed covalent modifications to proteins, along with pharmaceutical formulations and their applications. The second, "MK2 inhibitors and uses thereof," details compounds useful as inhibitors of MK2 kinases, including their formulations and methodologies. These advancements hold promise for new treatments in various medical fields.

Career Highlights: Zhendong Zhu has accumulated extensive experience working with notable companies in the pharmaceutical sector. He was involved with Celgene, a global biopharmaceutical company, where he contributed to innovative research and development. His roles at Celgene Car LLC and Celgene Avilomics Research, Inc. allowed him to enhance his expertise in drug development and therapeutic inventions.

Collaborations: Throughout his career, Zhendong Zhu has collaborated with fellow researchers, including Deqiang Niu and Russell Colyn Petter. These partnerships have enriched his research endeavors, fostering a collaborative environment that encourages exploration and innovation in drug discovery.

Conclusion: Zhendong Zhu's contributions to the field of enzyme inhibitors and protein modification through his substantial patent portfolio highlight his dedication to scientific advancement. His work not only pushes the boundaries of current research but also holds potential for significant impacts on future therapeutic developments. With a strong foundation in biochemistry and a record of innovation, Zhu continues to be a key figure in the ongoing quest for novel medical solutions.

Profile summary based on public USPTO records.